Lys Therapeutics

Lys Therapeutics is a pioneering biotechnology company revolutionizing the treatment of patients with neurodegenerative or neurovascular diseases by targeting blood-brain barrier (BBB) dysfunctions and neuroinflammation. In the pathophysiology of various neurological diseases such as stroke, multiple sclerosis, and Parkinsons disease, the hyperactivation of endothelial NMDA receptors (NMDAr) by tissue plasminogen activator (tPA) overexpressed in these patients leads to the degradation of tight junctions and BBB dysfunction, allowing the transmigration of inflammatory cells and toxic molecules into the brain parenchyma, triggering excitotoxicity and neuroinflammation, major contributors to neurodegeneration. Lys Therapeutics lead drug candidate, LYS241, is a first-in-class monoclonal antibody with a...

Stroke,multiple sclerosis,neurology,neurodegenerative disorders,healthcare,biotechnology,pharma,drug development,antibody,parkinson,parkinson's disease,and neurovascular diseases

Lys therapeutics operates in the Pharmaceutical manufacturing industry.

Lys therapeutics's revenue is 11m - 100m

Lys therapeutics has 11 - 50 employees.